Jan 9 Adaptimmune Therapeutics Plc
* Adaptimmune confirms gsk nomination of second adaptimmune target under strategic multi-target collaboration
* Adaptimmune therapeutics-under terms of deal,potential development milestones co eligible to get solely for prame program may amount to about $300 million Source text for Eikon: Further company coverage:
WORLD NEWS SCHEDULE AT 1800 GMT/2 PM ET
Iraqi forces free hundreds of civilians in Mosul Old City battles as death toll mounts
CEO of Raytheon's Forcepoint eyes IPO -Boersen-Zeitung
FRANKFURT, June 24 U.S. missile maker Raytheon's cybersecurity unit could thrive were it to be listed separately, the head of the unit, Forcepoint, told German business daily Boersenzeitung in an interview published on Saturday.